Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Net Income towards Common Stockholders (2018 - 2025)

Addex Therapeutics' Net Income towards Common Stockholders history spans 8 years, with the latest figure at -$6.0 million for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders rose 46.06% to -$6.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$7.5 million, a 457.16% decrease, with the full-year FY2025 number at -$8.1 million, down 200.75% from a year prior.
  • Net Income towards Common Stockholders came in at -$6.0 million for Q4 2025, down from $142225.5 in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $15.9 million in Q2 2024, with the low at -$23.2 million in Q4 2021.
  • Historically, Net Income towards Common Stockholders has averaged -$3.9 million across 5 years, with a median of -$2.9 million in 2021.
  • Biggest five-year swings in Net Income towards Common Stockholders: tumbled 796.04% in 2023 and later surged 761.78% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at -$23.2 million in 2021, then soared by 106.43% to $1.5 million in 2022, then crashed by 796.04% to -$10.4 million in 2023, then decreased by 6.67% to -$11.1 million in 2024, then soared by 46.06% to -$6.0 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for ADXN at -$6.0 million in Q4 2025, $142225.5 in Q2 2025, and -$1.6 million in Q1 2025.